
UROV
Healthcare · Biotechnology · $531.8M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2021
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 12, 2021 | After the close | -1.59 | -1.46 | +8.1% |
| Nov 2, 2020 | After the close | -1.42 | -1.12 | +21.4% |
| Aug 13, 2020 | After the close | -1.36 | -0.99 | +27.0% |
| Jun 18, 2020 | After the close | -1.12 | -1.68 | -50.0% |
| Feb 13, 2020 | After the close | -0.95 | -1.36 | -43.3% |
| Nov 5, 2019 | After the close | -0.98 | -0.85 | +13.1% |
| Aug 13, 2019 | After the close | -0.96 | -0.94 | +1.7% |
| Jun 13, 2019 | After the close | -0.94 | -0.96 | -1.7% |
| Feb 13, 2019 | After the close | -1.09 | -0.87 | +19.9% |
| Nov 12, 2018 | After the close | -1.43 | -1.09 | +23.6% |
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also…